查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1830985

卵巢癌药物市场

Ovarian Cancer Drugs Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

卵巢癌药物市场预计将从 2024 年的 24.3 亿美元扩大到 2031 年的 42.3 亿美元，预计 2025 年至 2031 年的复合年增长率为 7.1%。

市场洞察与分析师观点：卵巢癌发生率的不断上升推动了卵巢癌药物市场的成长。然而，由于副作用而导致的产品召回阻碍了市场扩张。

增长催化剂：卵巢癌发生率上升，刺激了对治疗方案的需求。卵巢癌是女性第七大常见癌症，也是第三大常见妇科癌症，仅次于子宫颈癌和子宫内膜癌。根据世界卵巢癌联盟统计，每年有32.4万名女性被诊断出罹患卵巢癌，其中20.7万人死于此病。由于缺乏用于早期发现的公共卫生筛检项目，大多数卵巢癌患者在确诊时已是晚期。因此，卵巢癌发生率的上升推动了对有效治疗方案的需求。对于新诊断为晚期卵巢癌的女性，标准的第一线治疗包括减瘤手术和铂类化疗的组合。此外，已获批准的PARP抑制剂，如奥拉帕尼、鲁卡帕尼和尼拉帕尼，代表了新诊断卵巢癌治疗的重大进展。事实证明，使用 PARP 抑制剂是治疗晚期卵巢癌的有效策略，可提高临床效果，并在对初始铂类化疗方案完全缓解 (CR) 后提供长期疗效和无恶化存活期 (PFS)。

策略洞察报告细分和范围：透过检查以下细分来分析卵巢癌药物市场：类型、药物类别和配销通路。

細項分析：市场依类型分为上皮性卵巢癌、生殖细胞卵巢癌和间质肿瘤。上皮性卵巢癌在2022年占据了卵巢癌药物市场的最大份额，预计在预测期内将达到8.2%的最高复合年增长率。根据英国癌症研究中心的数据，上皮性卵巢癌是最常见的卵巢癌类型，近90%的卵巢肿瘤本质上是上皮性肿瘤。晚期侵袭性卵巢癌患者的治疗选择有限。 2022年11月，美国食品药物管理局（FDA）批准了由Elahere ImmunoGen, Inc.开发的“mirvetuximab soravtansine-gynx”，用于治疗成人上皮性卵巢癌患者。此药物的建议剂量为6毫克/公斤，每三週静脉输註一次。 2024年1月，FDA授予「RC88」快速通道资格认定（FTD），这是一款针对间皮素的抗体-药物偶联物（ADC），旨在治疗復发性上皮性卵巢癌患者。因此，越来越多的药物获准正在推动卵巢癌药物市场的成长，尤其是在上皮性卵巢癌领域。

卵巢癌药物市场趋势联合药物治疗众多医学研究机构正在研究卵巢癌治疗的创新联合疗法。 2023 年 9 月，皇家马斯登医院的研究人员宣布了一种新的联合药物疗法，该疗法已显示出对晚期卵巢癌患者的有效性。这种联合疗法针对低度浆液性卵巢癌 (LGSOC) 进行了影响测试，LGSOC 是一种罕见的卵巢癌，通常对现有治疗反应不佳。 RAMP-201 临床试验结合了 avutometinib 和 defactinib 两种药物，以探索它们对 LGSOC 患者的协同作用。中期结果表明，接受这种联合治疗的患者中有 45% 的肿瘤明显缩小，几乎是曲美替尼 (trametinib) 有效性的两倍，而曲美替尼是一种反应率仅为 26% 的标靶治疗药物。 2024 年 1 月，FDA 批准了 SH-105 联合药物用于治疗乳癌和卵巢癌患者。因此，联合药物疗法正在成为一种新趋势，并可能在未来几年促进卵巢癌药物市场的成长。

区域分析：卵巢癌药物市场报告涵盖北美、欧洲、亚太地区、南美和中美以及中东和非洲等地区。 2022年，北美占据了卵巢癌药物市场的最大份额，这得益于领先公司推出的产品数量增加以及主要市场参与者的参与。美国是北美市场的主要贡献者。女性卵巢癌发生率的上升促使公司和监管机构在该地区开发和批准创新药物。此外，越来越多的合约临床研究组织 (CRO) 也支持了北美卵巢癌药物市场的成长。

卵巢癌药物市场报告范围：产业发展与未来机会：卵巢癌药物市场的预测可以帮助利害关係人规划其成长策略。以下是一些市场领导企业的策略发展：

2022年11月，ImmunoGen公司获得美国食品药物管理局（FDA）批准ELAHERE（mirvetuximab soravtansine-gynx）用于治疗铂类抗药性的成年上皮性卵巢癌患者。 ELAHERE被专门核准用于治疗FRα阳性的铂类抗药性卵巢癌患者。由于治疗方案有限且现有疗法的临床疗效不佳，这种卵巢癌治疗具有挑战性。竞争格局与重点公司：卵巢癌药物市场报告中介绍的知名公司包括礼来公司、阿斯特捷利康公司、葛兰素史克公司、Zielab公司、ImmunoGen公司（艾伯维公司）、GeneTech公司（罗氏公司）、Vivesto公司、Allarity Therapeutics公司、Aeterna Zentaris公司和绿叶製药公司。这些公司专注于开发新技术、改进现有产品并扩大其地域覆盖范围，以满足日益增长的全球需求。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：卵巢癌药物市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：卵巢癌药物市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：卵巢癌药物市场－全球市场分析

  • 卵巢癌药物－全球市场概览
  • 卵巢癌药物－全球市场及2031年预测

第七章：卵巢癌药物市场-收入分析-按类型，2021-2031

  • 概述
  • 上皮性卵巢癌
  • 生殖细胞卵巢癌
  • 间质肿瘤

第 8 章：卵巢癌药物市场 - 收入分析 - 按药物类别，2021-2031 年

  • 概述
  • PARP抑制剂
  • 抗血管新生抑制剂
  • 其他的

第九章：卵巢癌药物市场-收入分析-按配销通路，2021-2031

  • 概述
  • 医院药房
  • 零售药局
  • 其他的

第 10 章：卵巢癌药物市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 13 章：卵巢癌药物市场 - 关键公司简介

  • AbbVie Inc
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Pfizer, Inc.
  • Merck and Co., Inc.
  • ImmunoGen, Inc
  • CLOVIS ONCOLOGY
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline, Plc
  • Amgen Inc

第 14 章：附录

简介目录
Product Code: TIPRE00003750

The ovarian cancer drugs market is anticipated to expand from US$ 2.43 billion in 2024 to US$ 4.23 billion by 2031, reflecting a projected CAGR of 7.1% from 2025 to 2031.

Market Insights and Analyst Perspective:The increasing prevalence of ovarian cancer is driving the growth of the ovarian cancer drugs market. However, product recalls due to side effects are hindering market expansion.

Growth Catalysts:Increasing Incidence of Ovarian Cancer Fuels Demand for Treatment Options

Ovarian cancer ranks as the seventh most prevalent cancer among women and the third most common gynecological cancer, following cervical and endometrial cancers. According to the World Ovarian Cancer Coalition, 324,000 women are diagnosed with ovarian cancer each year, with 207,000 fatalities attributed to the disease. Most ovarian cancer patients are diagnosed at an advanced stage due to the absence of public health screening programs for early detection. Consequently, the rising incidence of ovarian cancer drives the need for effective treatment options. The standard first-line treatment for women newly diagnosed with advanced ovarian cancer involves a combination of debulking surgery and platinum-based chemotherapy. Additionally, approved PARP inhibitors such as olaparib, rucaparib, and niraparib represent significant advancements in managing newly diagnosed ovarian cancer. The use of PARP inhibitors has proven to be an effective therapeutic strategy for advanced ovarian cancer, enhancing clinical outcomes and providing long-term efficacy and progression-free survival (PFS) following a complete response (CR) to initial platinum-based chemotherapy regimens.

Strategic Insights

Report Segmentation and Scope:The analysis of the ovarian cancer drugs market has been conducted by examining the following segments: type, drug class, and distribution channel.

Segmental Analysis:The market is categorized by type into epithelial ovarian cancer, germ cell ovarian cancer, and stromal tumors. The epithelial ovarian cancer segment accounted for the largest share of the ovarian cancer drugs market in 2022 and is expected to achieve the highest CAGR of 8.2% during the forecast period. According to Cancer Research UK, epithelial ovarian cancer is the most prevalent form of ovarian cancer, with nearly 90% of ovarian tumors being epithelial in nature. Patients with aggressive, late-stage ovarian cancer face limited treatment options. In November 2022, the FDA approved "mirvetuximab soravtansine-gynx," developed by Elahere ImmunoGen, Inc., for adult patients with epithelial ovarian cancer. The recommended dosage for this drug is 6 mg/kg, administered as an IV infusion every three weeks. In January 2024, the FDA granted fast-track designation (FTD) for "RC88," a mesothelin-targeting antibody-drug conjugate (ADC) aimed at treating patients with recurrent epithelial ovarian cancer. Thus, the increasing number of drug approvals is driving growth in the ovarian cancer drugs market, particularly for the epithelial ovarian cancer segment.

Ovarian Cancer Drugs Market Trends

Combination Drug Therapy

Numerous medical research institutions are working on innovative combination therapies for ovarian cancer treatment. In September 2023, researchers at the Royal Marsden announced a new combination drug therapy that has shown effectiveness in patients with advanced ovarian cancer. This combination therapy was tested for its impact on low-grade serous ovarian cancer (LGSOC), a rare type of ovarian cancer that typically has a poor response to existing treatments. The RAMP-201 clinical trial combined the drugs avutometinib and defactinib to explore their synergistic effects in LGSOC patients. Interim results indicated that 45% of patients treated with this combination experienced significant tumor shrinkage, nearly double the effectiveness of trametinib, a targeted therapy with a response rate of only 26%. In January 2024, the FDA approved the SH-105 combination drug for treating patients with breast and ovarian cancer. Therefore, combination drug therapies are emerging as a new trend likely to enhance growth in the ovarian cancer drugs market in the coming years.

Regional Analysis:The ovarian cancer drugs market report covers regions including North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America held the largest share of the ovarian cancer drugs market, driven by an increase in product launches from leading companies and the presence of key market players. The US is the primary contributor to the market in North America. The rising incidence of ovarian cancer among women is prompting companies and regulatory bodies to develop and approve innovative drugs in this region. Additionally, the growing number of contract clinical research organizations (CROs) supports the growth of the ovarian cancer drugs market in North America.

Ovarian Cancer Drugs Market Report ScopeIndustry Developments and Future Opportunities:The forecast for the ovarian cancer drugs market can assist stakeholders in planning their growth strategies. Below are some strategic developments by leading players in the market:

In November 2022, ImmunoGen received FDA approval for ELAHERE (mirvetuximab soravtansine-gynx) to treat adult patients with platinum-resistant epithelial ovarian cancer. ELAHERE is specifically approved for patients with FRα-positive platinum-resistant ovarian cancer, a challenging condition due to limited treatment options and poor clinical outcomes from existing therapies.

Competitive Landscape and Key Companies:Prominent companies profiled in the ovarian cancer drugs market report include Eli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma. These companies are focused on developing new technologies, enhancing existing products, and expanding their geographic reach to meet the growing global demand.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Ovarian Cancer Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Ovarian Cancer Drugs Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Ovarian Cancer Drugs Market - Global Market Analysis

  • 6.1 Ovarian Cancer Drugs - Global Market Overview
  • 6.2 Ovarian Cancer Drugs - Global Market and Forecast to 2031

7. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million) - By Type, 2021-2031

  • 7.1 Overview
  • 7.2 Epithelial Ovarian Cancer
  • 7.3 Germ Cell Ovarian Cancer
  • 7.4 Stromal Tumors

8. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million) - By Drug Class, 2021-2031

  • 8.1 Overview
  • 8.2 PARP Inhibitors
  • 8.3 Anti-Angiogenesis Inhibitors
  • 8.4 Others

9. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Others

10. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Ovarian Cancer Drugs Market Overview
    • 10.1.2 North America Ovarian Cancer Drugs Market Revenue and Forecasts to 2031
    • 10.1.3 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Type
    • 10.1.4 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Drug Class
    • 10.1.5 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Ovarian Cancer Drugs Market
        • 10.1.6.1.1 United States Ovarian Cancer Drugs Market, by Type
        • 10.1.6.1.2 United States Ovarian Cancer Drugs Market, by Drug Class
        • 10.1.6.1.3 United States Ovarian Cancer Drugs Market, by Distribution Channel
      • 10.1.6.2 Canada Ovarian Cancer Drugs Market
        • 10.1.6.2.1 Canada Ovarian Cancer Drugs Market, by Type
        • 10.1.6.2.2 Canada Ovarian Cancer Drugs Market, by Drug Class
        • 10.1.6.2.3 Canada Ovarian Cancer Drugs Market, by Distribution Channel
      • 10.1.6.3 Mexico Ovarian Cancer Drugs Market
        • 10.1.6.3.1 Mexico Ovarian Cancer Drugs Market, by Type
        • 10.1.6.3.2 Mexico Ovarian Cancer Drugs Market, by Drug Class
        • 10.1.6.3.3 Mexico Ovarian Cancer Drugs Market, by Distribution Channel
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Ovarian Cancer Drugs Market - Key Company Profiles

  • 13.1 AbbVie Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 AstraZeneca
  • 13.3 F. Hoffmann-La Roche Ltd
  • 13.4 Pfizer, Inc.
  • 13.5 Merck and Co., Inc.
  • 13.6 ImmunoGen, Inc
  • 13.7 CLOVIS ONCOLOGY
  • 13.8 Boehringer Ingelheim International GmbH
  • 13.9 GlaxoSmithKline, Plc
  • 13.10 Amgen Inc

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud